Can-Fite Biopharma's Veterinary Partner Vetbiolix Completes Enrollment In Phase 2 Study Of Piclidenoson For Osteoarthritis In Dogs; Topline Data Are Expected In Q3 2026
Vetbiolix, Can-Fite's veterinary commercialization partner, is funding all development costs associated with the registration of Piclidenoson for osteoarthritis in companion animals.Vetbiolix has exercised its option to

































